|
1
|
Worni M, Guller U, White RR, Castleberry
AW, Pietrobon R, Cerny T, Gloor B and Koeberle D: Modest
improvement in overall survival for patients with metastatic
pancreatic cancer: A trend analysis using the surveillance,
epidemiology, and end results registry from 1988 to 2008. Pancreas.
42:1157–1163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bednar F and Simeone DM: Recent advances
in pancreatic surgery. Curr Opin Gastroenterol. 30:518–523. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottaiano A, Capozzi M, De Divitiis C, De
Stefano A, Botti G, Avallone A and Tafuto S: Gemcitabine
mono-therapy versus gemcitabine plus targeted therapy in advanced
pancreatic cancer: A meta-analysis of randomized phase III trials.
Acta Oncol. 56:377–383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghaneh P, Smith R, Tudor-Smith C, Raraty M
and Neoptolemos JP: Neoadjuvant and adjuvant strategies for
pancreatic cancer. Eur J Surg Oncol. 34:297–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Massari F, Santoni M, Ciccarese C,
Brunelli M, Conti A, Santini D, Montironi R, Cascinu S and Tortora
G: Emerging concepts on drug resistance in bladder cancer:
Implications for future strategies. Crit Rev Oncol Hematol.
96:81–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Sousa Cavalcante L and Monteiro G:
Gemcitabine: Metabolism and molecular mechanisms of action,
sensitivity and chemoresistance in pancreatic cancer. Eur J
Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miao X, Koch G, Ait-Oudhia S, Straubinger
RM and Jusko WJ: Pharmacodynamic modeling of cell cycle effects for
gemcitabine and trabectedin combinations in pancreatic cancer
cells. Front Pharmacol. 7:4212016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu P, Zhu Y, Yang C, Wang Y and Wang G:
Department of oncology, huangshan people's hospital, affiliated to
wangnan medical college: The mechanism and countermeasures on the
secondary resistance of epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI). Anti-Tumor Pharm. 5:42015.
|
|
10
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert G, Gaggioli C, Bailet O, Chavey C,
Abbe P, Aberdam E, Sabatié E, Cano A, Garcia de Herreros A,
Ballotti R and Tartare-Deckert S: SPARC represses E-cadherin and
induces mesenchymal transition during melanoma development. Cancer
Res. 66:7516–7523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
13
|
Neel DS and Bivona TG: Secrets of drug
resistance in NSCLC exposed by new molecular definition of EMT.
Clin Cancer Res. 19:3–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng
L, Shi Y, Wang H, Yin B, Xia J and Wang Z: Down-regulation of
miR-223 reverses epithelial-mesenchymal transition in
gemcitabine-resistant pancreatic cancer cells. Oncotarget.
6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maeda H, Wu J, Sawa T, Matsumura Y and
Hori K: Tumor vascular permeability and the EPR effect in
macromolecular therapeutics: A review. J Control Release.
65:271–284. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirui DK, Celia C, Molinaro R, Bansal SS,
Cosco D, Fresta M, Shen H and Ferrari M: Mild hyperthermia enhances
transport of liposomal gemcitabine and improves in vivo therapeutic
response. Adv Healthc Mater. 4:1092–1103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kimura-Tsuchiya R, Ishikawa T, Kokura S,
Mizushima K, Adachi S, Okajima M, Matsuyama T, Okayama T, Sakamoto
N, Katada K, et al: The inhibitory effect of heat treatment against
epithelial-mesenchymal transition (EMT) in human pancreatic
adenocarcinoma cell lines. J Clin Biochem Nutr. 55:56–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Y, Zhang J, Mi W, Yang J, Han F, Lu X
and Yu W: Silencing of GM3 synthase suppresses lung metastasis of
murine breast cancer cells. Breast Cancer Res. 10:R12008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rigg AS and Lemoine NR: Adenoviral
delivery of TIMP1 or TIMP2 can modify the invasive behavior of
pancreatic cancer and can have a significant antitumor effect in
vivo. Cancer Gene Ther. 8:869–878. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerald R and Meidel RS: Adenoviral
vectorsGlover DM and Hames BD: DNA Cloning 4. A Prac Appr. Oxford
Univ Press; Oxford: pp. 285–305. 1996
|
|
23
|
Mittereder N, March KL and Trapnell BC:
Evaluation of the concentration and bioactivity of adenovirus
vectors for gene therapy. J Virol. 70:7498–7509. 1996.PubMed/NCBI
|
|
24
|
Sun XF, Shao YB, Liu MG, Chen Q, Liu ZJ,
Xu B, Luo SX and Liu H: High-concentration glucose enhances
invasion in invasive ductal breast carcinoma by promoting
Glut1/MMP2/MMP9 axis expression. Oncol Lett. 13:2989–2995. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim CE, Lim SK and Kim JS: In vivo
antitumor effect of cromolyn in PEGylated liposomes for pancreatic
cancer. J Control Release. 157:190–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shamir ER and Ewald AJ: Adhesion in
mammary development: Novel roles for E-cadherin in individual and
collective cell migration. Curr Top Dev Biol. 112:353–382. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kowalski PJ, Rubin MA and Kleer CG:
E-cadherin expression in primary carcinomas of the breast and its
distant metastases. Breast Cancer Res. 5:R217–R222. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baruch RR, Melinscak H, Lo J, Liu Y, Yeung
O and Hurta RA: Altered matrix metalloproteinase expression
associated with oncogene-mediated cellular transformation and
metastasis formation. Cell Biol Int. 25:411–420. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacob A and Prekeris R: The regulation of
MMP targeting to invadopodia during cancer metastasis. Fron Cell
Dev Biol. 3:42015.
|
|
31
|
Chen Y, Yu Y, Sun S, Wang Z, Liu P, Liu S
and Jiang J: Bradykinin promotes migration and invasion of
hepatocellular carcinoma cells through TRPM7 and MMP2. Exp Cell
Res. 349:68–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jakubowska K, Pryczynicz A, Januszewska J,
Sidorkiewicz I, Kemona A, Niewiński A, Lewczuk Ł, Kędra B and
Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases 2,
7 and 9 in carcinogenesis of pancreatic ductal adenocarcinoma. Dis
Markers. 2016:98957212016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sawaji Y, Sato T, Seiki M and Ito A: Heat
shock-mediated transient increase in intracellular 3′,5′-cyclic AMP
results in tumor specific suppression of membrane type 1-matrix
metalloproteinase production and progelatinase A activation. Clin
Exp Metastasis. 18:131–138. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sternlicht MD and Werb Z: How matrix
metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol.
17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
|
